3-mandeloyloxy-8,8-dimethyl-nortropanium; bromide | 1082366-48-0

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: 3-mandeloyloxy-8,8-dimethyl-nortropanium; bromide
• 英文别名: 3-Mandeloyloxy-8,8-dimethyl-nortropanium; Bromid；N-Methylhomatropinium-bromid；Homatropin-methobromid；Methylhomatropine bromide；(8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl) 2-hydroxy-2-phenylacetate;bromide
• CAS: 1082366-48-0
• 化学式: Br*C₁₇H₂₄NO₃
• 分子量: 370.286
• InChiKey: FUFVKLQESJNNAN-UHFFFAOYSA-M

物化性质

• 熔点：
  191-192 °C

计算性质

• 辛醇/水分配系数(LogP)：
  -0.96
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  溴甲烷 、 Homatropine 在 乙醇 作用下， 生成 3-mandeloyloxy-8,8-dimethyl-nortropanium; bromide
  参考文献：
  名称：

  DE145996

  摘要：

  公开号：

文献信息

• [EN] PHARMACEUTICAL COMPOSITIONS OF POLYANIONIC AND NON-IONIC CYCLODEXTRIN-BASED DENDRIMERS AND USES THEREOF<br/>[FR] COMPOSITIONS PHARMACEUTIQUES DE DENDRIMÈRES À BASE DE CYCLODEXTRINE POLYANIONIQUE ET NON-IONIQUE ET UTILISATIONS ASSOCIÉES
  申请人：LING CHANG-CHUN

  公开号：WO2016161501A1

  公开（公告）日：2016-10-13

  The present application provides pharmaceutical compositions comprising polyanionic and polynon-ionic cyclodextrin-based dendrimers. The compositions can be used as excipients, or to bind to compounds such as in the use as a rescue medicine to remove undesired drugs and metabolites from a subject. Methods of use in treating a subject are also provided.

  当前申请提供了包含多阴离子和多非离子环糊精基树枝状聚合物的药物组合物。这些组合物可以用作辅料，或者用于结合化合物，例如用作救援药物以从主体中去除不需要的药物和代谢物。还提供了用于治疗主体的方法。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• MONOCYCLIC COMPOUNDS AND THEIR USE AS TRPV1 LIGANDS
  申请人：Tafesse Laykea

  公开号：US20100120862A1

  公开（公告）日：2010-05-13

  The invention relates to compounds of formula I and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof.

  本发明涉及公式I的化合物及其药学上可接受的衍生物，包括含有公式I化合物或其药学上可接受的衍生物的有效量的组合物，以及治疗或预防疼痛、尿失禁、溃疡、炎症性肠病（IBD）和肠易激综合征（IBS）等疾病的方法，包括向需要的动物施用公式I化合物或其药学上可接受的衍生物的有效量。
• HETEROCYCLIC TRPV1 RECEPTOR LIGANDS
  申请人：Tafesse Laykea

  公开号：US20100137306A1

  公开（公告）日：2010-06-03

  The invention relates to compounds of formulae I(a)-I(d): and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formulae I(a)-I(d) or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formulae I(a)-I(d) or a pharmaceutically acceptable derivative thereof.

  该发明涉及以下化合物的化学式：I(a)-I(d)，及其药学上可接受的衍生物，包括含有化合物I(a)-I(d)或其药学上可接受的衍生物的有效量的组合物，以及用于治疗或预防疼痛、尿失禁、溃疡、炎症性肠病和肠易激综合征等疾病的方法，包括向需要的动物施用化合物I(a)-I(d)或其药学上可接受的衍生物的有效量。
• BICYCLOHETEROARYL COMPOUNDS AND THEIR USE AS TRPV1 LIGANDS
  申请人：TAFESSE LAYKEA

  公开号：US20100130499A1

  公开（公告）日：2010-05-27

  The invention relates to compounds of formula I and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof.

  该发明涉及公式I的化合物及其药用可接受的衍生物，包含有效量的公式I化合物或其药用可接受的衍生物的组合物，以及治疗或预防疼痛、尿失禁、溃疡、炎症性肠病和肠易激综合征等疾病的方法，包括向需要治疗的动物施用公式I化合物或其药用可接受的衍生物的有效量。

表征谱图